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Supplemental Figure 1 27 
 28 
Supplemental Figure 1. MS2 spectrum (A) of the key metabolite marker (p-value < 0.0005), 29 
whereby the established fragmentation tree (B) suggested the identity of metformin. The Tier 30 
1 identification level was reached using an authentic reference standard, analyzed under 31 
identical analytical conditions.  32 
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Supplemental Figure 2 47 
 48 
Supplemental Figure 2: Marker metabolites that were identified as in-source fragments of 49 
metformin, presented below the metformin panel and organized according to the metformin 50 
fragmentation tree (Supplemental Figure 1). Marker metabolite that was identified as an 51 
alternative ionization adduct of metformin (i.e. addition of acetonitrile (ACN)), presented above 52 
the metformin panel. Fragments are indicated in red when corresponding to the metformin 53 
fragmentation pattern.  54 
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Supplemental Figure 3 56 
 57 
Supplemental Figure 3: Marker metabolites that were identified as products of metformin 58 
metabolization, as being mediated by the host or microbial community. Fragments were 59 
indicated in red when corresponding to the fragmentation pattern of metformin and in orange 60 
when considered supportive towards the identification process.  61 
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Supplemental Figure 4 62 
 63 
Supplemental Figure 4: MS2 spectrum that was obtained for the authentic reference standard 64 
of cholesterol. Fragments were indicated in red when corresponding to the fragmentation 65 
pattern that was obtained for the metformin-cholesterol condensation product.  66 
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Supplemental Table 1. Evaluation of BMI, gender, age, and metformin as potential 84 
confounding factors within the established clinical cohort and glycemic index (HbA1c)-based 85 
classes. To this end, restructuring of the datasets and evaluation of the validation parameters 86 
of the associated OPLS-DA models (excluding specific confounding factors) was performed.  87 
OPLS-DA model description Q2 p-value 
Impact of metformin treatment 
  
1) Lipidomics LC-MS, after removal of metformin-related metabolites;  
normal glycemic state (n = 21) vs. type 2 diabetes (n = 21) 
0.619 0.001 
2) Polar LC-MS, after removal of metformin-related metabolites;  
normal glycemic state (n = 21) vs. type 2 diabetes (n = 21) 
0.697 1.05 e-6 
3) LA-REIMS, after removal of metformin-related metabolites;  
normal glycemic state (n = 36) vs. type 2 diabetes (n = 38) 
0.524 4.04 e-9 
Impact of BMI (also after removal of the metformin-related fraction)   
1) Lipidomics LC-MS, after BMI-matching; normal glycemic state (n = 12, BMI 
26.7 ± 2.5 kg/m2) vs. type 2 diabetes (n = 12, BMI 28.6 ± 2.2 kg/m2) 
0.349 0.070 
2) Polar LC-MS, after BMI-matching; normal glycemic state (n = 12, BMI 26.7 ± 
2.5 kg/m2) vs. type 2 diabetes (n = 12, BMI 28.6 ± 2.2 kg/m2) 
0.692 0.008 
3) LA-REIMS, after BMI-matching; normal glycemic state (n = 24, BMI 25.5 ± 2.7 
kg/m2) vs. type 2 diabetes (n = 24, BMI 28.8 ± 3.1 kg/m2) 
0.480 9.3 e-5 
Impact of gender (also after removal of the metformin-related fraction)   
1) Lipidomics LC-MS, considering only male participants;  
normal glycemic state (n = 8) vs. type 2 diabetes (n = 18) 
0.514 0.020 
2) Lipidomics LC-MS, considering only female participants;  
normal glycemic state (n = 12) vs. type 2 diabetes (n = 4) 
0.498 0.001 
3) Polar LC-MS, considering only male participants;  
normal glycemic state (n = 8) vs. type 2 diabetes (n = 18) 
0.666 0.005 
4) Polar LC-MS, considering only female participants;  
normal glycemic state (n = 8) vs. type 2 diabetes (n = 18) 
0.656 0.013 
5) LA-REIMS LC-MS, considering only male participants;  
normal glycemic state (n = 13) vs. type 2 diabetes (n = 25) 
0.511 0.001 
6) LA-REIMS LC-MS, considering only female participants;  
normal glycemic state (n = 23) vs. type 2 diabetes (n = 12) 
0.324 0.280 
Impact of BMI (also after removal of the metformin-related fraction)   
1) Lipidomics LC-MS, after age-matching; normal glycemic state (n = 12, 51.9 ± 
4.8 years) vs. type 2 diabetes (n = 12, age 57.0 ± 4.8 years) 
0.350 0.070 
2) Polar LC-MS, after age-matching; normal glycemic state (n = 12, 51.9 ± 4.8 
years) vs. type 2 diabetes (n = 12, age 57.0 ± 4.8 years) 
0.698 0.007 
3) LA-REIMS, after age-matching; normal glycemic state (n = 28, 54.2 ± 5.2 
years) vs. type 2 diabetes (n = 28, age 57.1 ± 5.2 years) 
0.505 3.10 e-6 
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Supplemental Table 2. Chemical information of UHPLC-HRMS markers that were revealed 88 
upon discriminative fingerprinting by lipidomics or polar metabolomics.  89 
Lipidomics Polar metabolomics 
m/z-value (Da) Ion Rt (min) m/z-value (Da) Ion Rt (min) 
85.0515a [M+H]+ 1.38 60.0564a [M+H]+ 1.09 
88.0875a [M+H]+ 1.38 71.0610a [M+H]+ 1.07 
130.1089a [M+H]+ 1.38 83.0347  [M-H]- 1.07 
263.1066 [M+H]+ 1.66 85.0514a [M+H]+ 1.07 
271.1516 [M+H]+ 1.38 86.0589 [M+H]+ 1.09 
280.2347 [M+H]+ 1.82 88.0874a [M+H]+ 1.07 
280.2347 [M+H]+ 2.65 111.0661 [M-H]- 1.07 
280.2350 [M+H]+ 2.26 113.0820a [M+H]+ 1.07 
283.1150 [M+H]+ 1.40 114.0855 [M+H]+ 1.09 
299.1467 [M+H]+ 1.38 126.0220 [M+H]+ 1.00 
317.2087 [M+H]+ 2.33 130.1086a [M+H]+ 1.05 
323.1470 [M+H]+ 1.43 158.1400 [M+H]+ 4.49 
323.2191 [M+H]+ 3.89 160.1191b [M+H]+ 1.51 
327.1776 [M+H]+ 1.44 171.1350a [M+ACN+H]+ 1.09 
327.1778 [M+H]+ 1.71 179.0337 [M+H]+ 3.11 
341.2057 [M+H]+ 2.28 181.0523 [M-H]- 6.09 
341.2060 [M+H]+ 2.68 184.0827 [M+H]+ 2.31 
372.3110 [M+H]+ 3.90 184.1191b [M+H]+ 1.73 
378.3589 [M+H]+ 5.99 185.1223 [M+H]+ 1.69 
387.2885 [M+H]+ 6.65 202.1296 [M+H]+ 3.72 
398.3990 [M+H]+ 8.28 214.1295 [M+H]+ 1.42 
411.2867 [M+H]+ 5.79 228.1452 [M+H]+ 2.48 
411.2869 [M+H]+ 6.24 244.1399b [M+H]+ 1.43 
414.3212 [M+H]+ 3.62 247.1873b [M+H]+ 1.18 
416.3368 [M+H]+ 4.19 253.1541 [M+H]+ 0.94 
424.3421 [M+H]+ 5.09 258.1557 [M+H]+ 1.54 
426.3578 [M+H]+ 5.26 259.2094b [M+H]+ 1.03 
440.3732 [M+H]+ 5.60 261.2027b [M+H]+ 0.99 
442.3527 [M+H]+ 4.75 262.2061 [M+H]+ 1.06 
444.3682 [M+H]+ 5.05 267.1559 [M+H]+ 1.04 
448.3408 [M+H]+ 5.24 273.2028 [M+H]+ 1.12 
452.3734 [M+H]+ 5.62 274.0681 [M+H]+ 1.20 
464.3194 [M+H]+ 6.19 274.1503b [M+H]+ 1.18 
468.3688 [M+H]+ 5.18 274.2060 [M+H]+ 1.04 
470.2868 [M+H]+ 1.64 289.2342 [M+H]+ 1.58 
470.3840 [M+H]+ 5.57 291.2133b [M+H]+ 1.05 
483.2133 [M-H]- 1.43 295.1860b [M+H]+ 1.09 
496.3997 [M+H]+ 5.83 297.1831 [M+H]+ 1.05 
498.4530 b [M+H]+ 7.60 308.1446 [M+H]+ 1.39 
534.5237 [M+H]+ 8.02 339.1923 [M-H]- 7.95 
599.3795 [M+H]+ 1.94 341.2064 [M+H]+ 7.97 
600.5079 [M+H]+ 14.81 369.2376 [M+H]+ 9.37 
615.5401 [M-H]- 8.18 396.1507 [M+H]+ 5.8 
646.5135 [M-H]- 7.25 434.2867 [M+H]+ 9.29 
667.6411 [M+H]+ 9.76 462.2402 [M-H]- 2.34 
 8 
685.5773 [M+H]+ 11.18    
694.5765 [M+H]+ 9.00    
694.5768 [M+H]+ 10.14    
696.5917 [M+H]+ 9.10    
696.5920 [M+H]+ 9.85    
703.5048 [M+H]+ 6.30    
719.5356 [M+H]+ 6.95    
824.7695 [M+H]+ 12.77    
912.7606 [M+H]+ 12.98    
a Metformin or related features, i.e. in-source fragments  90 
b Metformin metabolization products 91 
